MOLECUBES

Today we’re celebrating Belgian National Day! 🇧🇪    A great moment to also look back on our own Belgian roots 👇    CUBES started in 2015 as a spin-off from Ghent University. Our founders had deep roots in preclinical imaging and saw a clear gap for CT/PET/SPECT imaging systems that are benchtop, modular, and scalable without compromising performance.    Ten years after our first SPECT CUBE launched, the team has been working nonstop to build the next-generation SPECT, based on what our customers need: detecting low biological signals and imaging high-energy radionuclides.    From a small idea in Ghent to preclinical imaging in labs all around the world: a big thanks to our team and customers who are part of the CUBES journey ◻️🫶🏻 

We are moving! 🚚    The latest CUBES information now lives on the Bruker website:    ✔️ Webinars and white papers  ✔️ Sales contact  ✔️ Customer support       Time to update the bookmarks 📎  New address: https://lnkd.in/eaMmgBM8 Bruker BioSpin Bruker Preclinical Imaging

💡 Can a third drug turn a partial response into a durable one?    Discover the β-CUBE (PET) in action 🔬    PSMA radioligand therapy is a real advance for castration-resistant prostate cancer, but even with immune checkpoint inhibition added on top, it isn’t curative on its own.     This study by Camilla Locatelli et al., from University Hospital Essen, tested whether an ENPP1 inhibitor, acting on the STING pathway and adenosine signaling, could improve therapy response further.     How much did the third mechanism actually add?  👇 Scroll through the carousel for the results 

Scanning four animals at once doesn't mean averaging their welfare. Each one gets its own read on temperature, heart rate, and breathing.    From standard mouse or rat imaging to multi-animal workflows and biocontainment applications, the CUBES offer a range of animal beds designed to support different research needs while maintaining stable physiological monitoring for each animal.     One of the newest additions is the BioShield Mouse Cradle: a sealed, air-filtered cradle that enables controlled positive- or negative-pressure environments, with continuous monitoring of pressure and physiological parameters throughout the imaging workflow.    👉Swipe through for an overview of the CUBES animal bed range, what gets monitored during a scan, and where the new BioShield Mouse Cradle fits in. 

Kicking off the summer weather the best way we know how: with a CUBES team BBQ! ☀️🍔    The team assembled for an evening of cooking, dinner, and drinks (heat wave very much included 🔥)  Behind the scenes though, things are picking up pace.     We’ve still got CUBES to deliver to their new homes this summer, and internally we've got our hands on our next generation SPECT CUBE.    We can’t wait to share more with you soon! ⬜️

Redesigning SPECT: 𝗧𝗵𝗲 𝗻𝗲𝘅𝘁 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 γ-𝗖𝗨𝗕𝗘    The  𝗻𝗲𝘄 γ-𝗖𝗨𝗕𝗘 enables detection of smaller or lower-uptake biological signals, quantification of high-energy radionucleotides (such as iodine-131, lead-212, actinium-225) and true dynamic SPECT imaging.    Built around   ◻️An improved sensitivity-resolution balance  ◻️Reliable imaging of high-energy therapeutic radionuclides  ◻️The familiar, highly intuitive CUBEflow software     Experimental requirements in preclinical SPECT imaging are steadily evolving. The γ-CUBE is here to support these evolving needs.    We’re excited to see the discoveries it will contribute to.    Stay tuned for more! 😉 Download our new whitepaper to learn how we built a system that support modern-day SPECT research: https://lnkd.in/eMKGUSSB

💡 Can RNA therapy be delivered straight to fibrotic lungs without breaking down before it gets there?    Discover the β-CUBE (PET) and X-CUBE (CT) in action 🔬    This study by Itziar Souto Riobó et al., from CIC biomaGUNE, packaged antifibrotic microRNA-29 into pulmonary surfactant nanoparticles, designed to protect the RNA and improve uptake by lung cells. The nanoparticles were tested in a bleomycin-induced pulmonary fibrosis mouse model.    PET imaging with the β-CUBE mapped where the nanoparticles went after intratracheal delivery, while the X-CUBE tracked fibrosis progression and lung volume over the course of treatment.    Where did the nanoparticles end up, and did the therapy actually slow fibrosis down?    👇 Scroll through the carousel to find out